TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Recruiting

Back to Small Cell Lung Cancer ( SCLC ) trials

Early Phase 1 — The very first tests in people. Usually just a handful of volunteers, to check the treatment is safe enough to keep studying.

Trial locations(1 site)

China

The Jinling Hospital, Nanjing, Jiangsu

Key details

Phase

Very early testing

Sponsor

TCRCure Biopharma Ltd.

Collaborators

The Jinling Hospital

Enrollment target

~24 participants

Started

November 2025

Primary completion

November 2027

Age range

18 Years – 75 Years

Last updated November 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov

TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC — Stella